Glycolysis and glucose metabolism as a target for bioenergetic and neuronal protection in glaucoma

Pete A. Williams*, Robert J. Casson

Vision is arguably our most valued sense, yet approximately 340 million people globally suffer blindness or moderate visual impairment, highlighting the need to further develop and advance treatments for ophthalmic diseases. Glaucoma refers to a group of ocular disorders united by a clinically characteristic optic neuropathy with associated retinal ganglion cell loss. It is one of the most prevalent neurodegenerations globally, the leading cause of irreversible blindness, and affects ~80 million people worldwide (with an estimated further 40 million undiagnosed).

The major risk factors for glaucoma are advancing age, genetics, and high intraocular pressure (IOP). Current treatment strategies only target IOP lowering. Although under careful management, vision can usually be preserved, after 20 years, approximately 15% of individuals have progressed to bilateral blindness (Peters et al., 2013). Furthermore, increased life expectancies are making life-long retention of vision more challenging. Clinically translatable therapeutic strategies for glaucoma that do not target IOP lowering are urgently needed. Recently we demonstrated a strong neuroprotection in multiple cell and animal models of glaucoma-related injury focusing on pyruvate metabolism which was successfully translated into a Phase II randomized control clinical trial. Here we discuss the potential to target retinal ganglion cell metabolism via glycolysis/glycose metabolism for neuroprotection in glaucoma. An overview of these strategies is presented in Figure 1.

The intense energy requirements of the brain render it susceptible to bioenergetic failure. It is notable that bioenergetic dysfunction has been implicated in a variety of neurodegenerative diseases, at the level of glycolysis and oxidative phosphorylation. Parkinsonism is associated with phosphoglycerate kinase deficiency, which catalyzes the first ATP-producing reaction in glycolysis (Tang, 2020). Brain regions with the highest levels of glycolysis in adulthood are those that have the highest susceptibility to Alzheimer’s disease (Tang, 2020). Similarly, motor neuron disorder is also associated with bioenergetic abnormalities and aerobic glycolysis (Tang, 2020).

Figure 1 | Manipulating glucose metabolism in glaucoma.

Retinal ganglion cells derive adenosine triphosphate (ATP) from glycolysis and oxidative phosphorylation (OXPHOS). Glucose enters retinal ganglion cells via glucose transporters (glut), and the vitreous can serve as a reservoir. Nicotinamide dinucleotide (NAD) is a critical redox molecule required for glycolysis and formed by the tricarboxylic acid cycle (TCA) as an electron donor and can be derived from oral nicotinamide. Pyruvate is converted to lactate in a reversible reaction catalyzed by the isoenzymes lactate dehydrogenase A (LDHA) and LDHB. MCT1: Monocarboxylate transporter 1. Created with Inkscape (https://inkscape.org/).

Lactate is also an important energy source for neurons. The monocarboxylate transporter 1 (MCT1) allows the transport of lactate through the blood-brain barrier as well as the inner and outer blood-retina barrier. Supporting a hypothesis in which pyruvate and lactate are important metabolites to retinal ganglion cells, both mitochondrial pyruvate carriers 1 and 2 (MPC1 and MPC2) have been demonstrated to be present at high levels in retinal ganglion cells.
across a number of species (Chidlow et al., 2005; Harder et al., 2020). Lactate and pyruvate are strongly neuroprotective to retinal ganglion cells in culture, including under glucose deprivation (Harder et al., 2020). Studies utilizing D2 mice and a mouse model of ocular hypertension have demonstrated reduced levels of L-lactate and a reduction in pyruvate protein levels with MCT2 receptor overexpression demonstrated to be neuroprotective (Harun-Or-Rashid et al., 2020). Supporting this, pharmacological inhibition of MCTs blocks the neuroprotective effects of pyruvate on cultured retinal ganglion cells. Collectively, these experiments provide strong evidence for the role for glycolysis as a target for neuroprotection in glaucoma.

Pyruvate is an ideal treatment to test for clinical use, with a long history and good safety profiles in humans (with the only major side effect being diarrhea, typically when taken at greater than 30 g/day). To increase the neuroprotective capacity of pyruvate we tested a combination therapy of pyruvate and nicotinamide. Nicotinamide has been demonstrated to be strongly neuroprotective at high doses (Williams et al., 2017; Tribble et al., 2021). Combination therapy of pyruvate and nicotinamide (at lower doses than used individually) lowered the risk of optic nerve degeneration in D2 mouse by ~2.6 fold, more than either treatment alone.

But how do we translate this increasing knowledge of bioenergetic and glycolytic vulnerabilities in glaucoma animal models into clinically available neuroprotective strategies for glaucoma? Our first clues come from a study from Casson and colleagues who performed a double-blind randomized study testing 50% glucose eye drops versus saline (Casson et al., 2014). In this study, primary open-angle glaucoma patients were randomly allocated saline or 50% glucose eye drops every 5 minutes for 60 minutes (Casson et al., 2014). Glucose successfully reached the vitreous of pseudophakic individuals and glucose eye drops significantly improved contrast sensitivity over control. These data support an earlier study in which elevating intravitreal glucose levels provides neuroprotection in a rat model of retinal ischemia and, together, supports the notion of bioenergetically compromised retinal ganglion cells as a target for recovery.

Given these exciting short-term findings in glaucoma patients with glucose eye drops, and our results demonstrating a strong neuroprotection with pyruvate and nicotinamide in glaucoma animal models, we next set off to apply this in a clinical trial setting. To test pyruvate and nicotinamide in combination (our most neuroprotective setting in glaucoma models), De Moraes et al. (2022) performed a randomized Phase II clinical trial testing pyruvate 3 g/day plus nicotinamide 3 g/day in primary open-angle glaucoma patients. This study demonstrated improved visual function (pattern standard deviation (visual field)) in existing glaucoma patients versus placebo control (average 2 months follow-up) in addition to high adherence rates (only 1 patient withdrawn and no reported adverse effects). If we take the pre-clinical and clinical data in concert, then this paints an attractive narrative, where pyruvate not only provides neuroprotection, but also provides neurorecovery with improved visual function. Importantly, these approaches are directly therapeutically approachable and, if combined with IOP-lowering therapies – the current gold standard in glaucoma – represent a powerful therapeutic strategy for human glaucoma.

The mechanism underpinning intraocular pressure-associated glaucomatous axonal degeneration remains unclear. However, there is considerable evidence that vascular insufficiency at the level of the optic nerve head and the retina plays a role. This is particularly prominent in normal-tension glaucoma, one could speculate that bioenergetic strategies would be particularly suited to this form of glaucoma. However, targeting glycolysis at the level of the retinal ganglion cells presents challenges. Persistently, elevating vitreous glucose levels, for example, by some method of local administration may cause profound diabetic retinopathy (whether elevated vitreal glucose in the absence of hyperglycemia would actually cause a retinal microangiopathy is untested). Oral supplements may need to be in supraphysiologic concentrations to reach therapeutic levels, and gene therapy manipulation of glycolytic enzymes may have unexpected adverse consequences. Future research in retinal bioenergetics will encompass benchwork aiming to better understand energy metabolism at the cell-specific level and translation to clinical trials. Interrogating in vivo metabolism is challenging and will benefit from emerging technologies such as hyperspectral imaging. A better understanding of what retinal ganglion cells ‘like to eat’ will guide optimal translation. In addition, the field is likely to benefit from advances in gene therapy, CRISPR approaches, and targeted manipulation of glycolytic enzymes. Alternative methods of manipulating metabolism with visible light are being investigated. Clinical neuroprotection research in glaucoma is in its infancy but is benefiting from collaborative strategies and sophisticated trial designs.

Recent clinical and pre-clinical evidence suggests that retinal ganglion cells have the capacity to recover function and is supported by evidence that initial IOP-lowering leads to a transient increase or recovery of functional vision. Together, this has introduced the concept of the “coma in glaucoma”, the idea that retinal ganglion cells undergoing neurodegenerative cascades are part of a heterogenous population of dead, dying, stressed, and alive cells – a critical plastic state that is amenable to functional recovery if the right conditions are met (Fry et al., 2018). If energy failure is part of the pathogenesis then it is logical that bioenergetic strategies may support neurorecovery and, in the chronic situation, support neuroprotection in a manner analogous to intracellular pressure reduction.

This work was supported by Karolinska Institutet in the form of a Board of Research Faculty Funded Career Position, by St. Erik Eye Hospital philanthropic donations, and Vetenskapsrådet 2022-00799 (to PAW). PAW is an Alcon Research Funded Career Position. PAW is an Alcon Research Young Investigator.

Pete A. Williams*, Robert J. Casson
Department of Clinical Neuroscience, Division of Eye and Vision, St. Erik Eye Hospital, Karolinska Institute, Stockholm, Sweden (Williams PA)
Ophthalmic Research Laboratories, Discipline of Ophthalmology and Visual Sciences, University of Adelaide, Adelaide, Australia (Casson RJ)

*Correspondence to: Pete A. Williams, PhD, pete.williams@ki.se.
https://orcid.org/0000-0001-6194-8397

Date of submission: August 14, 2023
Date of decision: September 21, 2023
Date of acceptance: October 9, 2023
Date of web publication: December 11, 2023

https://doi.org/10.4103/1673-5374.389638

How to cite this article: Williams PA, Casson RJ (2024) Glycolysis and glucose metabolism as a target for bioenergetic and neuronal protection in glaucoma. Neural Regen Res 19(8):1637-1638.

Open access statement: This is an open access journal, and articles are distributed under the terms of the Creative Commons AttributionNonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

References


E-Ceditors: Zhao M, Sun Y, Qiu Y, T-Editor: Jia Y

1638 | NEURAL REGENERATION RESEARCH | Vol 19 | No. 8 | August 2024